Abstract
Overview
Introduction
Drug repositioning has several advantages over traditional discovery-reduced
cost, risk and time to market-compared with traditional discovery, providing
an attractive prospect for Big Pharma, scrambling to fill pipelines in an
increasingly harsh market environment. As competition to inlicense candidates
drives the price of this strategy up, repositioning presents a cost effective
alternative.
Scope
- An outline of what drug repositioning is, and what is driving it.
- An overview of the key players in the repositioning industry their
methodologies and specialities.
- Case-studies describing a number of drugs which are or have been
repositioned.
- An insight into how repositioning will change going forward.
Highlights
Despite increasing R&D investment, productivity has been declining, at a time
when Big Pharma is contending with latestage pipeline failures and more
rigorous drug approval procedures, in addition to external challenges in the
form of generic competition and pricing pressures.
The cost savings, accelerated path to market, and lower risks that
repositioning brings relative to traditional discovery are attractive to Big
Pharma, which has thus far been filling pipeline gaps by inlicensing, a
practice which has become more expensive as competition for candidates
increases.
The companies involved in repositioning currently differ greatly in the
methodologies used, in addition to their disease focus, however as the
strategy gains traction, the industry is likely to undergo considerable
consolidation.
Reasons to Purchase
- Understand what drug repositioning is, and why it is important.
- Become aware of who the key players in drug repositioning are and how they
operate.
- Gain an insight into how drugs have been, and are being repositioned.
View Cart
